IL

Illumina IncXETRA Illumina Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

20.521

Large

Exchange

XETR - Xetra

ILU.DE Stock Analysis

IL

Uncovered

Illumina Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-14/100

Low score

Market cap $B

20.521

Dividend yield

Shares outstanding

158 B

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 11,500 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

View Section: Eyestock Rating